TD Cowen Raises Incyte (INCY) Price Target to $140

On October 21, 2026, TD Cowen maintained its Buy rating on Incyte Corporation (NasdaqGS: INCY) while raising its price target from $138.00 to $140.00. The research note highlights confidence in the biotechnology firm's ongoing drug discovery and commercialization efforts as market participants await fresh financial updates.

INCY Incyte Corporation

$113.44 ▲ +11.85% year to date

1M 3M YTD

Daily close · Oct 21, 2026

TD Cowen's Call on Incyte Corporation

In its research note published on October 21, 2026, TD Cowen kept a Buy rating on the stock while moving its target up to $140.00 from $138.00. The firm looks forward to upcoming catalysts for the biopharmaceutical developer, which works on medical therapeutics across multiple global regions.

Other Institutional Activity in Incyte Corporation

Large asset managers adjusted their holdings in Incyte Corporation during recent reporting periods. Baker Bros. Advisors, LP grew its holdings by 18,446 shares, ending with 30,762,330 shares worth about $3,544,897,116.0. Dodge & Cox Inc. reduced its stake by 295,288 shares, ending with 11,957,326 shares valued at roughly $1,377,902,468.0. AQR Capital Management, LLC trimmed its position by 487,309 shares, leaving it with 5,320,901 shares worth about $613,154,029.0. Meanwhile, LSV Asset Management grew its stake by 203,836 shares, or 5.2%, to hold 4,123,759 shares valued at roughly $475,201,370.0.

Incyte Corporation Stock Up 2.5%

Incyte Corporation shares recently traded around $116.31 as of October 22, 2026, sitting up about 2.5% compared to the closing price of $113.44 on the day of TD Cowen's note. The stock has a trailing price-to-earnings ratio of 14.68, and its next earnings report is scheduled for October 29, 2026.

Recent Earnings

Incyte Corporation generated trailing-twelve-month revenue of $5.82 billion alongside basic earnings of $7.85 per share. The company reported a net profit margin of 27.7% and a return on equity of 30.7% over the same period, reflecting solid operational profitability.

Insider Buying and Selling at Incyte Corporation

Company insiders have transacted in shares over recent months. Officer Pablo J Cagnoni executed multiple sales, including 10,803 shares on August 12, 2026, for $1296792.0, 10,801 shares on August 19, 2026, for $1356174.0, 23,218 shares on September 15, 2026, for $2797629.0, and 2,642 shares on October 15, 2026, for $297780.0.

Analysts Set New Price Targets

Wall Street firms frequently update their outlooks on the healthcare company. On October 5, 2026, Stifel maintained a Buy rating and raised its target to $157.00 from $145.00. RBC Capital maintained a Sector Perform rating on October 8, 2026, moving its target from $109.00 to $114.00. HC Wainwright & Co. reiterated a Buy rating on October 13, 2026, keeping its target at $152.00. Truist Securities maintained a Hold rating on October 14, 2026, raising its target from $105.00 to $115.00. Overall, the stock carries a consensus buy recommendation from 24 analysts with a mean price target of $129.54.

About Incyte Corporation

Incyte Corporation discovers, develops, and brings to market specialized medical therapeutics. Operating out of Wilmington, Delaware, the biotechnology firm focuses on addressing unmet medical needs through targeted therapies for patients in the United States, Europe, Canada, and Japan. Analyst updates like TD Cowen's revised target help investors gauge market expectations as the company advances its clinical pipeline.

Bottom Line

Investors will look closely at Incyte Corporation's upcoming earnings release on October 29, 2026, for fresh details on revenue growth and drug sales. Monitoring institutional filing updates and subsequent analyst notes will provide additional clarity on how the broader market values the company's treatment portfolio.